Patient Square Capital LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 12, 2026), Patient Square Capital LP reported 23 stock positions worth $645.5 million. Its top holding was Roivant Sciences (ROIV) at 44.0% of the portfolio, followed by Revolution Medicines (RVMD, 8.0%) and Mirum Pharmaceuticals (MIRM, 4.7%). Compared with Q1 2026, it opened 6 new positions, sold out of 12, added to 9 and reduced 8. The biggest buy was a new position in Revolution Medicines (RVMD) and the biggest sale an exit from Insmed (INSM).
- Most Recent 13F
- Q2 2026
- Location
- MENLO PARK, CA
- CIK
- 0001819257
- Portfolio Value
- $645.5M (Q2 2026)
- SEC Filing
- 0001819257-26-000005 ↗ filed Aug 12, 2026
Holdings Value
Holdings 23 stocks · $645.5M
| ROIV Roivant Sciences Ltd. | 43.97% | 8,020,928 | $283.9M | Reduce -1.8% |
| RVMD Revolution Medicines Inc. | 8.01% | 276,000 | $51.7M | New |
| MIRM Mirum Pharmaceuticals Inc. | 4.72% | 260,500 | $30.5M | Add +13.3% |
| ABVX Abivax SA-ADR | 4.26% | 206,500 | $27.5M | Add +70.3% |
| ONC Beone Medicines Ltd.-ADR | 3.97% | 90,020 | $25.7M | Add +11.8% |
| PHVS Pharvaris NV | 3.60% | 671,209 | $23.2M | Add +36.1% |
| ARGX Argenx SE - ADR | 3.31% | 23,000 | $21.3M | Reduce -37.4% |
| UTHR United Therapeutics Corp. | 3.12% | 37,120 | $20.1M | New |
| BLTE Belite Bio Inc. - ADR | 2.62% | 110,000 | $16.9M | Reduce -5.7% |
| COGT Cogent Biosciences Inc. | 2.55% | 425,000 | $16.4M | Reduce -28.7% |
| DBVT DBV Technologies SA-Spon ADR | 2.31% | 909,474 | $14.9M | Add +31.1% |
| XENE Xenon Pharmaceuticals Inc. | 2.06% | 220,000 | $13.3M | Reduce -3.1% |
| BNTX Biontech SE-ADR | 1.94% | 134,429 | $12.5M | New |
| RCUS Arcus Biosciences Inc. | 1.70% | 355,800 | $11.0M | Add +82.5% |
| ELVN Enliven Therapeutics Inc. | 1.67% | 212,500 | $10.8M | Add +6.3% |
| DNTH Dianthus Therapeutics Inc. | 1.63% | 108,000 | $10.5M | Add +15.0% |
| ALLO Allogene Therapeutics Inc. | 1.63% | 5,050,000 | $10.5M | Add +46.4% |
| EYPT Eyepoint Inc. | 1.59% | 720,000 | $10.3M | Reduce -9.4% |
| ARQT Arcutis Biotherapeutics Inc. | 1.50% | 370,000 | $9.7M | Reduce -7.7% |
| CCCC C4 Therapeutics Inc. | 1.16% | 1,608,815 | $7.5M | New |
| IVA Inventiva SA - ADR | 1.15% | 1,967,171 | $7.4M | New |
| KYMR Kymera Therapeutics Inc. | 0.84% | 47,500 | $5.4M | Reduce -52.5% |
| FTH Faeth Therapeutics Inc. | 0.68% | 175,050 | $4.4M | New |
Portfolio Sells Q1 2026 → Q2 2026
| INSM Insmed Inc. | Sold out | 0.00% | −4.57 |
| LEGN Legend Biotech Corp.-ADR | Sold out | 0.00% | −3.18 |
| NKTR Nektar Therapeutics | Sold out | 0.00% | −2.68 |
| CELC Celcuity Inc. | Sold out | 0.00% | −1.92 |
| MRK Merck & Co. Inc. | Sold out | 0.00% | −1.71 |
| COGT Cogent Biosciences Inc. | Reduce -28.7% | 2.55% | −1.52 |
| ARGX Argenx SE - ADR | Reduce -37.4% | 3.31% | −1.45 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −1.20 |
| DFTX Definium Therapeutics Inc. | Sold out | 0.00% | −1.11 |
| HROW Harrow Inc. | Sold out | 0.00% | −1.03 |
| TARA Protara Therapeutic Inc. | Sold out | 0.00% | −0.95 |
| CTMX Cytomx Therapeutics Inc. | Sold out | 0.00% | −0.91 |
| BLTE Belite Bio Inc. - ADR | Reduce -5.7% | 2.62% | −0.68 |
| ASMB Assembly Biosciences Inc. | Sold out | 0.00% | −0.67 |
| KYMR Kymera Therapeutics Inc. | Reduce -52.5% | 0.84% | −0.63 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -3.1% | 2.06% | −0.28 |
| EYPT Eyepoint Inc. | Reduce -9.4% | 1.59% | −0.22 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -7.7% | 1.50% | −0.17 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −0.01 |
| ROIV Roivant Sciences Ltd. | Reduce -1.8% | 43.97% | +3.84 |
Portfolio Buys Q1 2026 → Q2 2026
| RVMD Revolution Medicines Inc. | New | 8.01% | +8.01 |
| UTHR United Therapeutics Corp. | New | 3.12% | +3.12 |
| BNTX Biontech SE-ADR | New | 1.94% | +1.94 |
| ABVX Abivax SA-ADR | Add +70.3% | 4.26% | +1.87 |
| CCCC C4 Therapeutics Inc. | New | 1.16% | +1.16 |
| IVA Inventiva SA - ADR | New | 1.15% | +1.15 |
| PHVS Pharvaris NV | Add +36.1% | 3.60% | +1.12 |
| MIRM Mirum Pharmaceuticals Inc. | Add +13.3% | 4.72% | +0.95 |
| RCUS Arcus Biosciences Inc. | Add +82.5% | 1.70% | +0.95 |
| FTH Faeth Therapeutics Inc. | New | 0.68% | +0.68 |
| ELVN Enliven Therapeutics Inc. | Add +6.3% | 1.67% | +0.28 |
| DNTH Dianthus Therapeutics Inc. | Add +15.0% | 1.63% | +0.23 |
| ALLO Allogene Therapeutics Inc. | Add +46.4% | 1.63% | +0.13 |
| DBVT DBV Technologies SA-Spon ADR | Add +31.1% | 2.31% | −0.26 |
| ONC Beone Medicines Ltd.-ADR | Add +11.8% | 3.97% | −0.27 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $645.5M | ROIV, RVMD, MIRM, ABVX, ONC |
| Q1 2026 | 29 | $563.6M | ROIV, ARGX, INSM, ONC, COGT |
| Q4 2025 | 28 | $467.1M | ROIV, INSM, MIRM, ARGX, ONC |
| Q3 2025 | 24 | $373.9M | ROIV, INSM, EYPT, ABVX, CDTX |
| Q2 2025 | 19 | $277.4M | ROIV, INSM, ARGX, EYPT, LQDA |
| Q1 2025 | 19 | $241.7M | ROIV, INSM, LQDA, EYPT, OCUL |
| Q4 2024 | 20 | $267.4M | ROIV, LQDA, INSM, CGEM, EYPT |
| Q3 2024 | 11 | $269.4M | ROIV, LQDA, CGEM, INSM, EYPT |
| Q2 2024 | 2 | $215.4M | ROIV, LQDA |
| Q1 2024 | 2 | $234.8M | ROIV, LQDA |